Presenting at a prestigious conference like AACR significantly boosts a company's visibility in the scientific and investment communities. Early positive clinical experience with QN-302 could lead to increased investor confidence, potentially driving up the stock price in the short term. However, the impact is contingent on the broader market's reception of this news and the detailed results presented.